aselizumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 457820597

| type = mab

| mab_type = mab

| source = zu/o

| target = CD62L

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 395639-53-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 8Y539D78FU

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.{{cite journal | vauthors = Seekamp A, van Griensven M, Dhondt E, Diefenbeck M, Demeyer I, Vundelinckx G, Haas N, Schaechinger U, Wolowicka L, Rammelt S, Stroobants J, Marzi I, Brambrink AM, Dziurdzik P, Gasiorowski J, Redl H, Beckert M, Khan-Boluki J | display-authors = 6 | title = The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial | journal = Critical Care Medicine | volume = 32 | issue = 10 | pages = 2021–8 | date = October 2004 | pmid = 15483410 | doi = 10.1097/01.CCM.0000142396.59236.F3 | s2cid = 21172224 }}